|
Jan 11
|
Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene
|
|
Dec 8
|
Ligand (LGND) Up 12.4% Since Last Earnings Report: Can It Continue?
|
|
Dec 6
|
Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City
|
|
Dec 1
|
Here's Why Ligand Pharmaceuticals (LGND) is a Strong Value Stock
|
|
Dec 1
|
Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications
|
|
Nov 28
|
Tharimmune (THAR) Up on Positive Data From Pipeline Candidate
|
|
Nov 28
|
Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium
|
|
Nov 28
|
Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study
|
|
Nov 27
|
Regeneron (REGN), Sanofi's Dupixent Succeeds in 2nd COPD Study
|
|
Nov 27
|
Theseus (THRX) Up 57% in a Month on Strategic Restructuring Plan
|
|
Sep 8
|
Novan reaches deals to sell assets in bankruptcy case
|
|
Sep 7
|
Ligand (LGND) Down 8.8% Since Last Earnings Report: Can It Rebound?
|
|
Jul 11
|
Ligand Pharmaceuticals (LGND) Stock Sinks As Market Gains: What You Should Know
|
|
Jul 11
|
LGND or ILMN: Which Is the Better Value Stock Right Now?
|
|
Jul 11
|
Investors in Ligand Pharmaceuticals (NASDAQ:LGND) have unfortunately lost 51% over the last five years
|
|
Apr 28
|
Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Up Y/Y
|
|
Apr 27
|
Alkermes (ALKS) Q1 Earnings & Revenues Beat Estimates
|